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Introduction 
Bronchial responsiveness constitutes the 
phenomenon of the occurrence of airways 
obstruction upon physical, chemical and phar- 
macological stimuli (l-3). The clinical presen- 
tation in asthmatic individuals includes wheeze, 
cough and/or dyspnoea upon exercise and inha- 
lation of e.g. cold air, fog and perfume. The 
prevalence of bronchial hyper-responsiveness 
(BHR) in the population varies from 6 to 35% 
(4-14) and is strongly associated with the 
presence of respiratory symptoms. Even though 
BHR is generally accompanied by respiratory 
symptoms, population studies have shown that 
it may also occur in subjects without any 
respiratory symptom, so-called asymptomatic 
hyper-responsiveness (69,12,15). 
There is increasing evidence that an inflam- 
matory process in the airway wall is one of 
the underlying pathophysiologic mechanisms of 
BHR in asthma. This inflammatory process may 
directly or indirectly cause smooth muscle con- 
traction, airway wall oedema, and stimulation of 
the nervous system, leading to symptoms of 
cough, wheeze and dyspnoea. It is still unclear 
whether an inflammatory process is also present 
in asymptomatic individuals, and if so, whether 
it has similar cellular components. Furthermore, 
it is important to assess whether asympto- 
matic hyper-responsiveness has any prognostic 
importance as an early sign of disease 
development. 
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Department of Pulmonary Diseases, University Hospital 
Groningen, Hanzeplein 1, NL-9713 EZ Groningen, The 
Netherlands. 
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This review aims to synthesize the available 
literature with respect to the epidemiology and 
the prognostic significance, as well as the 
pathogenesis, of asymptomatic BHR; the latter 
specifically with respect to inflammation. 
Epidemiology of Asymptomatic Bronchial 
Hyper-responsiveness 
Epidemiologic studies in children (8,9) and 
adults (7,16,17) have shown that BHR is signifi- 
cantly associated with respiratory symptoms 
such as wheeze, breathlessness during the day 
or night, chest tightness, chronic (productive) 
cough and nocturnal cough. Bronchial respon- 
siveness has a continuous unimodal, log-normal 
distribution in the general population with 
asthmatic subjects at the more responsive end of 
the distribution (6,9,11,18,19). Thus, the more 
responsive a subject is, the more likely it is that 
he or she experiences respiratory symptoms. 
However, even among subjects with a very low 
value of PCZo, some are asymptomatic (6,18,19). 
In the various studies, the sensitivity of a BHR 
test, i.e. the fraction of symptomatic individuals 
identified by a positive bronchial challenge test, 
ranges from 0.29 to 0.61 in a random sample of 
the population (9,16,19,20). At the other end of 
the distribution, some subjects with high values 
of PC,, nevertheless reported respiratory symp- 
toms. In various studies, the specificity, i.e. the 
fraction of asymptomatic individuals identified 
by a negative bronchial challenge test, varies 
from 0.58 to 0.90. The accuracy, defined as the 
number of symptomatic individuals with BHR 
and asymptomatic individuals without BHR 
divided by the total number of individuals, 
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FIG. 1. Frequency distribution of percent change in 
FEV, from post-saline value after a cumulative dose 
of 3.9pmol histamine (total, n=2045; diagnosed 
asthmatics, shown by solid bars, n=294). Published 
with permission of Patternore et al. (9). 
ranges from 0.56 to O-85. As a result of this 
wide overlap between asymptomatic and symp- 
tomatic subjects, the predictive value of a posi- 
tive bronchial challenge test for the presence 
of respiratory symptoms appears to be low 
(Fig. 1). 
In 1947, Curry et al. found BHR to be present 
in subjects without respiratory symptoms (21). 
Recent population studies have confirmed the 
presence of BHR in asymptomatic subjects 
(Table l), the prevalence varying from 2.2 to 
14.3%. The wide range may be due to the use of 
different methods for assessment of BHR. Most 
studies have used histamine as the provocative 
stimulus, other stimuli being methacholine and 
cold air. Although histamine and, particularly, 
methacholine act directly, and cold air acts 
indirectly on the smooth muscle (24), the degree 
of bronchial responsiveness to methacholine 
correlates well with the degree of bronchial 
responsiveness to cold air (25), and the observed 
differences in prevalence cannot simply be 
explained by the use of different stimuli 
(Table 1). 
The range in prevalence rates may also result 
from varying definitions of asymptomatic state 
(8,9). The inclusion of a doctor’s diagnosis of 
asthma besides other respiratory symptoms 
decreased the prevalence from 6.5 to 5.5% in one 
study (9), and from 7.2 to 6.7% in another study 
(8). Asymptomatic BHR ranged from 4.5% in 
subjects reporting never to have experienced 
respiratory symptoms or rhinitis, to 9.3% in 
subjects without a medical history of asthma. 
The use of different recollection time periods, 
i.e. reporting respiratory symptoms in the 
12 months prior to the study, or ever in the past, 
does not seem to influence the prevalence 
rates (20). 
Cross-sectional epidemiologic studies may, 
therefore, show that whatever the definition of 
BHR and the symptomatic state, a considerable 
number of subjects with BHR are asymptomatic. 
Several factors have been put forward to 
explain asymptomatic hyper-responsiveness. 
First, the threshold level for BHR may be too 
high and has to be reduced. However, the 
overlap in bronchial responsiveness makes it 
impossible to make a clear distinction between 
symptomatic and asymptomatic subjects. Even 
when a lower threshold level is used to define 
BHR, BHR will still be present in asymptomatic 
subjects. 
Second, the presence of BHR can be tran- 
sient in time (26-28). Factors such as viral 
respiratory infections (29,30), occupational sen- 
sitizers (3 1,32) and allergen exposure (33) may be 
responsible for the temporal increase in bron- 
chial responsiveness in asymptomatic subjects. 
In standardized lung function testing, however, 
it is recommended to measure bronchial respon- 
siveness at least 2 weeks after a viral respiratory 
infection (34). Furthermore, most subjects 
sensitive to occupational sensitizers or allergen 
exposure will report respiratory symptoms. 
Thus, it seems plausible that other factors 
beside these transient factors play a role in 
asymptomatic hyper-responsiveness. 
Third, asymptomatic BHR may be explained 
by factors, other than respiratory symptoms, 
associated with BHR. Population studies have 
shown that the prevalence of BHR tends to be 
higher in older subjects (35,36), females (35,37), 
subjects who are atopic (4,6,35-40), who smoke 
cigarettes (4,6,36,40), or have pre-existent bron- 
chial obstruction (36-38,4143). How far symp- 
tom status may influence these relationships has 
been examined in few studies. One study showed 
a greater increase of bronchial responsiveness 
with age in symptomatic subjects (35). Another 
study showed that symptomatic children with 
BHR were more frequently sensitized to house- 
dust mite and pollen than asymptomatic children 
with BHR (44). The relationship between BHR 
and gender (35), smoking status (35) and 
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pulmonary function (35,38) appeared to be 
independent of the presence or absence of respir- 
atory symptoms. Other factors that may relate 
differently to BHR depending on symptom 
status are parental smoking and a positive family 
history of asthma. The association between 
parental smoking and bronchial responsiveness 
has been reported to be less strong (45) in 
asymptomatic children than in asthmatic symp- 
tomatic children, or even absent in asympto- 
matic children (46). In asymptomatic children, 
an increase in bronchial responsiveness to cold 
air was associated with a positive family history 
of asthma, while this association was not present 
in symptomatic children (47). Thus, the relation- 
ship between BHR and age, atopy and parental 
smoking appears to be stronger in symptomatic 
than in asymptomatic subjects, in contrast to the 
association between a family history of asthma 
and BHR, which appears to be stronger in 
asymptomatic subjects. 
Finally, asymptomatic subjects may not rec- 
ognize variable airway obstruction as breathless- 
ness. To examine whether asymptomatic subjects 
perceive breathlessness differently from sympto- 
matic subjects, Brand et al. (48) compared the 
Borg score reported by these two groups during 
histamine-induced bronchoconstriction. At the 
same degree of bronchoconstriction, sympto- 
matic hyper-responsive subjects were more likely 
to show an increase in the Borg score during a 
20% fall in FEV, than asymptomatic hyper- 
responsive subjects (Fig. 2), independent of age, 
gender, smoking habits, FEV, and atopy 
(P=O.O49). In a study conducted by Stenton 
et al. (49), a comparison was made between 
respiratory symptoms reported by questionnaire, 
BHR to methacholine, and the recognition of 
bronchoconstriction. After a decrease in FEV, 
of 20% or more, subjects were asked whether 
they had ever felt like that before. Recognition 
of this feeling was associated with the severity 
of bronchial responsiveness, i.e. all subjects 
in the most responsive category, and only 
27% in the least responsive group recognized 
the feeling of bronchoconstriction. Two-thirds 
of the subjects with intermediate bronchial 
responsiveness and who reported respiratory 
symptoms, such as wheeze, chest tightness, 
breathlessness and cough, did not recognize the 
feeling of bronchoconstriction. Further, there 
Borg score prior to histamine challenge 
FIG. 2. Relationship between Borg score and 
age- and height-adjusted FEV, before histamine 
challenge in men (0) and women (m). Bars represent 
SEM. Differences in age- and height-adjusted FEV, 
between subjects with different Borg scores are 
significant in men (ANOVA, P=O.Ol) but not in 
women (P=O.710). The number of subjects 
(M=men, W=women) is indicated on the x-axis 
for each Borg score category. Published with 
permission of Brand et al. (48). 
were also subjects who reported no respiratory 
symptoms but recognized the feeling of 
bronchoconstriction. 
The clinical relevance of asymptomatic hyper- 
responsiveness is unclear. Longitudinal popu- 
lation studies have shown a faster decline of 
pulmonary function in subjects \;i;ith BHR com- 
pared to subjects without BHR, independent of 
symptom status, smoking, atopy, pre-challenge 
FEV,, age, gender and height (50-52). Further, 
the severity of bronchial responsiveness was 
positively associated with the degree of pulmo- 
nary decline (10). From these data, the question 
was raised whether BHR might be a predictor 
for the subsequent unfolding of respiratory 
symptoms (Table 2). 
A study in 236 children, aged 8-11 years, 
assessed the predictive nature of BHR and 
wheeze for childhood respiratory illness during 
1 yr of follow-up (44). Children with BHR but 
no wheeze at baseline had more frequent respir- 
atory symptoms and more severe bronchial 
responsiveness during 1 yr of follow-up than 
those who did not have BHR and wheeze at 
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FIG. 3. Mean dose-response ratio in children 
classified according to baseline data. The points 
represent data collected in summer (S), autumn (A), 
winter (W) and spring (Sp). The bars are the 95% 
confidence intervals. Published with permission of 
Peat et al. (44). 
baseline, and less so than those who already had 
symptoms and BHR at baseline (Fig. 3). Similar 
findings have been described for exercise- 
induced asthma in children (54), and in studies 
by Hopp et al. (53) and Zhong et al. (55) in 
populations aged 5-44 years and 11-17 years, 
respectively. The last two studies compared 
asymptomatic subjects who developed asthma 
during the follow-up period, and age- and sex- 
matched controls who remained asymptomatic 
during the study. Twenty percent of the asymp- 
tomatic BHR students in Zhong et al’s study 
developed asthma after 2 yr of follow-up. 
Almost all subjects who developed asthma dur- 
ing the follow-up period in these studies had 
more severe bronchial responsiveness at the 
initial visit. The four subjects in the study of 
Hopp et al. (53) and six of the eight children in 
the study of Jones et al. (54), who developed 
asthma but did not have increased bronchial 
responsiveness at the initial visit, had siblings 
with asthma. 
Overall, the studies suggest that asymptomatic 
BHR, in any case in childhood and young adult- 
hood, may precede the unfolding of respiratory 
symptoms (Table 2). Research into broncho- 
alveolar lavage or biopsy parameters from the 
airways may indicate whether an underlying 
inflammatory mechanism is responsible for the 
presence of BHR in asymptomatic subjects. 
At present, there are no epidemiologic data 
available in this respect. 
Inflammation 
INFLAMMATION AS UNDERLYING 
MECHANISM OF BHR 
In both human and animal studies, inflamma- 
tory changes in the airways, such as viral infec- 
tions (29), allergen exposure (33), occupational 
(toluene diisocyanate) exposure (31) and ozone 
inhalation (58), have been shown to induce a 
temporal increase in bronchial responsiveness. 
Initially, information on the inflammatory pro- 
cess in the airways was largely based on autopsy 
findings of patients with severe asthma (59). 
The inflammatory changes which have been 
described include severe damage of airway epi- 
thelium, an extensive mucosal and submucosal 
infiltration by inflammatory cells, such as 
eosinophil granulocytes, and airway luminal 
obstruction by mucus and cellular debris (60,61). 
The relevance of these airway changes in autopsy 
studies to day-to-day asthma was first uncertain. 
Later studies in airway wall biopsies of patients 
with stable asthma revealed qualitative changes 
similar to autopsy findings in severe asthma 
patients (60,62-70). Many cells are activated, 
e.g. an increased proportion of eosinophils are 
EG2 positive (62,64,70-72). At present, the role 
of neutrophils in this process is uncertain 
(60,61,73,74). Apart from the cellular process, 
it is likely that an imbalance in the neuronal 
control of the airways plays a role in inflamma- 
tion by activation of sensory fibres which release 
mediators, such as substance P and neurokinins 
A and B (60). 
The changes described in bronchoalveolar 
lavage (BAL) are largely concordant with the 
histologic findings, and include an increased 
number of desquamated epithelial cells (63,67), 
(activated) inflammatory cells, such as eosino- 
phils (73,75,76), mast cells (67,73,77) and 
macrophages (7879). Furthermore, increased 
concentrations of inflammatory mediators in 
BAL fluid have been reported, compatible with 
activation of these cells (73,75,76,80-83). The 
inflammatory process in the airways can also be 
assessed by cell counts in sputum (obtained 
spontaneously or induced by hypertonic saline), 
a less invasive technique. compared to bron- 
choscopy. In asthma, percentages of eosinophils 
(84,85), mast cells (84) and neutrophils (84) 
are increased, whereas the percentage of 
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macrophages is decreased (84,85). Total cell 
counts and differential counts of intact epithelial 
cells and lymphocytes are not increased in 
asthma (84). These findings are confirmed for 
asthmatics with a mild exacerbation compared 
to smokers with chronic bronchitis, except for 
the numbers of neutrophils which were not 
different (86). 
Mast cells are known as prominent effector 
cells in IgE-mediated asthmatic reactions 
(60,61,74). Their numbers do not seem to be 
increased in the submucosa of patients with mild 
asthma. However, increased numbers of mast 
cells have been demonstrated (87) by electron 
microscopic (EM) investigation of bronchial epi- 
thelium. Furthermore, evidence has been found 
for mast cell degranulation (60,61,63,73). The 
increased numbers or activation state of mast 
cells has been confirmed by the presence of 
increased concentrations of mast cell mediators 
in BAL fluid (80,81). Mast cells secrete a wide 
array of pre-formed and newly formed media- 
tors, such as histamine, PgD2, LTC4, chymase 
and tryptase (60,61,74), and interleukins such as 
IL-4 (61,68). This interleukin has the potential to 
induce the immune ‘switching’ of B-lymphocytes 
to immunoglobin production, and to upregulate 
the expression of the adhesion molecule VCAM 1 
on the endothelial surface (61,89-91). Eosino- 
phils may adhere to these endothelial cells 
by binding to VCAMl and ICAM- 1 through 
specific integrin ligands (VLA4 and LFA-1, 
respectively), which enables their migration to 
the bronchial mucosa (60). IL-4 may be secreted 
in the course of IgE-mediated reactions, and this 
may imply that the mast cell has an even more 
important role in the regulation of the ongoing 
allergic reaction. 
T-lymphocytes play a very important regulat- 
ory role in the inflammatory processes of allergic 
asthma. The T-helper cell population (CD4 
positive) can be subdivided into Thl and Th2 
cells with specific features of each subgroup 
(60,61,74,92). These subsets are also character- 
ized by production of specific cytokines. As IL-4, 
IL-5 and IFN, are cytokines, mutually exclusive 
in their presence in Thl and Th2 cells, these 
proteins are relevant parameters to determine. 
The evaluation of the presence of Thl or Th2 
cells may give a clue to distinguish the various 
circumstances that lead to inflammation. In 
general, Thl cells are found in (viral) infections 
and not in asthmatic individuals $vith increased 
airway responsiveness, while conversely the 
presence of Th2 cells, in general, may be an 
indicator for an allergic component (61,92-94). 
In the induction phase of the allergic inflam- 
mation, B-cells (61), macrophages (61) or den- 
dritic cells present in the bronchial epithelium 
(95), act as antigen-presenting cells (APC) (96) 
interacting with T-cells (ThO-cells), which 
respond by differentiating to Th2 cells, a subtype 
that is capable of generating IL-3, IL-4, IL-5 and 
GM-CSF (61,92-95). IL-3, IL-5 and GM-CSF 
play a role in the activation and prolongation 
of the survival of eosinophil granulocytes 
(60,74,97). The possible role of IL-4 was 
discussed above. 
The eosinophil granulocyte is another potent 
inflammatory effector cell. Eosinophils are 
attracted to the bronchial mucosa and activated 
by many stimuli, such as leukotriene C4, platelet 
activating factor, IL-4 and IL-5. Once activated, 
eosinophils release newly formed mediators, 
including leukotrienes, PAF, 15-HETE and 
arginine-rich proteins, such as MBP, ECP and 
EPO (60,61,74). These agents may cause epi- 
thelial injury and denudation, probably due to 
disruption of desmosomal attachments between 
epithelial cells (62,67,70). This may result in an 
increased permeability to irritant stimuli for 
sensory nerves, thereby further inducing inflam- 
matory changes as well as an increase in airway 
responsiveness (66,98-100). 
As to the relation between these inflammatory 
changes and BHR in stable asthma, positive 
correlations have been described between the 
degree of bronchial responsiveness and the 
number of epithelial cells (63,76), eosinophils 
(76, lOl), mast cells (67,77,102), macrophages 
(103) and activated T-cells (104) in the BAL 
fluid. No relationship was observed between 
BHR and the number of neutrophils in BAL 
(63,76,77,103). Sputum cell counts were not 
related to bronchial responsiveness to hypertonic 
saline (85), histamine (105) and methacholine 
(86). However, a decrease in PC,, histamine was 
significantly associated with an increase in 
numbers of eosinophils and mast cells after 
allergen challenge (105). In bronchial biopsies, 
the level of bronchial responsiveness was related 
to increased numbers of mast cells (70,106), 
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dendritic cells (106), T-cells expressing IL-2 
receptors (70), and raised levels of HLA-DR 
expression (107). A similar relationship was 
observed between bronchial responsiveness and 
the cytokines IL-5 and GM-CSF independent of 
atopic status, while IL-2 correlated with BHR 
in non-atopic subjects (106). IL-3 and TNF-a 
showed no correlation with BHR. However, 
in vitro (108) and in vivo (109-l 11) studies in 
humans and in animals have shown the ability 
of TNF-a to increase bronchial responsiveness. 
Moreover, there was a positive correlation 
between the number of activated eosinophils in 
the biopsy specimens and the degree of bronchial 
responsiveness (64,70,72,106,112). 
INFLAMMATION AND ASYMPTOMATIC BHR 
The above findings suggest that inflammatory 
changes play a role in symptomatic individuals 
with BHR. It can be hypothesized that the 
difference between symptomatic and asympto- 
matic hyper-responsive individuals is the result 
of differences in inflammatory cell numbers, 
composition or activation. Little is known about 
the relationship between BHR and the presence 
of inflammatory cells in the airways in asympto- 
matic, non-asthmatic subjects. One study in 
asymptomatic hyper-responsive males showed 
that the levels of peripheral blood eosinophil 
counts were intermediate between symptomatic 
hyper-responsive males and asymptomatic nor- 
mal responsive males, independent of smoking 
status and age (113). No differences were 
observed between the groups with regard to 
neutrophils. These findings suggest a relation- 
ship between BHR and inflammatory changes in 
peripheral blood, which may reflect the situation 
in the airways of asymptomatic hyper-responsive 
subjects. This gives support to other studies 
finding (see above) that asymptomatic hyper- 
responsiveness may precede the development of 
symptomatic asthma. However, the two biopsy 
studies available are less clear whether this is the 
case. One study found an association of BHR 
with inflammatory changes in bronchial biopsies 
in healthy individuals with a ‘positive respiratory 
record’ (114), but not in subjects with asympto- 
matic BHR without a respiratory record. The 
subjects with positive respiratory records were, 
however, more hyper-responsive. Another study 
only investigated asymptomatic individuals. The 
authors did not find differences in numbers of 
neutrophils, T-cells, eosinophils and mast cells, 
nor in the expression of HLA-DR in bronchial 
biopsies of asymptomatic individuals with and 
without BHR. However, the combined use of 
the monoclonal antibodies RFD1 and RFD7 
showed changes in macrophage subsets. Finally, 
Roisman et al. recently assessed breathlessness 
during a 20% fall in FEV, upon methacholine 
and bradykinin challenge in hyper-responsive 
asthmatic individuals (115). More shedding of 
epithelium in airway wall biopsies was associated 
with less breathlessness during bronchoconstric- 
tion by either agent, possibly due to intra- 
epithelial nerve injury which is associated with 
epithelial damage in asthma. It might, thus, even 
be possible that asymptomatic asthma is associ- 
ated with epithelial damage, which may lead to 
symptomatic asthma upon allergen or irritant 
exposure. This can be compatible with the 
finding that sputum of asymptomatic hyper- 
responsive children contained less mast cells, 
basophils and eosinophils compared to sympto- 
matic hyper-responsive children, but similar 
numbers as in asymptomatic normal responsive 
children (116). Furthermore, Sur et al. (117) 
found that EDN and IL-5 levels in BAL fluid 
were significantly higher in symptomatic asthma 
patients than asymptomatic ones. IL-5 levels 
were especially high in symptomatic individuals 
with high numbers of eosinophils, suggesting 
increasing inflammation when asthma progresses 
from the asymptomatic to symptomatic state 
(Fig. 4). Altogether, the data suggest that 
higher environmental exposure induces the 
influx of cells which only asserts symptoms when 
epithelial damage is already present. 
Discussion and Conclusions 
Cross-sectional population studies investigating 
the relationship between BHR and respiratory 
symptoms have shown that BHR is significantly 
associated with respiratory symptoms, such as 
wheeze, breathlessness and chest tightness. How- 
ever, a positive bronchoprovocation challenge is 
neither a very sensitive nor a predictive indicator 
for the presence of respiratory symptoms. Ques- 
tionnaire responses as to respiratory complaints 
do not accurately reflect previous experience of 
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FIG. 4. Bronchoalveolar lavage (BAL) levels of 
eosinophil-derived neurotoxin (EDN) in patients 
with symptomatic asthma. BAL fluids from patients 
with symptomatic and asymptomatic asthma were 
analysed for the presence of EDN with a competi- 
tive binding radioimmunoassay. All values are 
expressed as ng ml - ’ in unconcentrated BAL fluids. 
The four patients with symptomatic asthma 
depicted with * had EDN levels > 500 ng ml - ’ 
(3387 ng ml- ‘, 2700 ng ml-‘, 941 ng ml- ‘, and 
737 ng ml - ‘). Published with permission of Sur 
et al. (117). Solid bars, symptomatic asthma; 
open bars, asymptomatic asthma. 
bronchoconstriction. Although the prevalence in 
the population is low, varying from 2.2 to 14*3%, 
a significant proportion of subjects with BHR is 
asymptomatic. There is no cut-off point of BHR 
to distinguish completely symptomatic from 
asymptomatic subjects. The variability of BHR 
in time, a poor perception of airways obstruction 
and a poorer association of BHR with older 
age, cigarette smoking, atopy and pre-existent 
bronchial obstruction in asymptomatic hyper- 
responsive individuals can only explain part 
of the phenomenon of asymptomatic hyper- 
responsiveness. An important finding is that 
asymptomatic subjects with BHR are more 
prone to develop respiratory symptoms than 
asymptomatic subjects without BHR. 
It is likely that inflammatory changes in the 
airways are the underlying mechanisms for BHR 
in asymptomatic subjects as well. Current studies 
in asthma suggest that an intricate interaction 
between different types of inflammatory cells and 
their respective mediators plays a role in the 
processes that lead to increased bronchial 
responsiveness. Only a few studies have exam- 
ined the presence of inflammatory changes in 
asymptomatic subjects with BHR. Although the 
number of eosinophils in peripheral blood was 
found to be increased in asymptomatic subjects 
with BHR compared with asymptomatic sub- 
jects without BHR, BHR was not found to be 
associated with overall inflammatory changes in 
the airways. However, one study did suggest that 
increasing inflammation is associated with pro- 
gression of an asymptomatic to a symptomatic 
state. Furthermore, it is possible that handling of 
inhaled irritants and viral infections is different 
in asymptomatic individuals with and without 
BHR, thereby ultimately leading to a different 
clinical outcome. Therefore, the role of airway 
mucosal inflammatory processes in the occur- 
rence of mild degrees of BHR in asymptomatic 
subjects should be a subject of further studies. 
These studies should’ preferably not only be 
of cross-sectional nature, but should also include 
follow-up of individuals. Only this will allow us 
to answer the question whether asymptomatic 
BHR is a risk factor for development of asthma 
(or chronic obstructive pulmonary disease), and 
whether there is a pathophysiologic inflamma- 
tory pathway in which we may interfere to 
prevent this unwanted development. 
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